Treatment of Mildly to Moderately Active Crohn's Disease with Ileocecal Involvement

This page addresses management of mildly to moderately active Crohn's disease affecting the terminal ileum and right colon (ileocecal region) in patients assessed as low risk for disease progression.

Clinical Scenario

Mildly to moderately active Crohn's disease with ileocecal (terminal ileum and right colon) involvement, in a patient with low risk for disease progression.

Treatment Approach

The evidence-based approach for this scenario centres on a specific oral corticosteroid formulation designed for targeted ileal delivery to induce symptomatic remission. For patients with mild disease and low risk of progression, a dietary strategy with close monitoring represents a recognised alternative. The complete regimen — including selection criteria, monitoring schedule, and full sequencing — is in the structured protocol.

Treatment Goals

Induction of symptomatic remission
Clinical evidence of improvement within 2–4 weeks
Maximal improvement by 12–16 weeks

Instant Access to Structured Evidence-Based Regimens

References

DOI: 10.14309/ajg.0000000000003465

We recommend controlled ileal release budesonide at a dose of 9 mg daily for induction of symptomatic remission in patients with mildly to moderately active ileocecal CD (strong recommendation, moderate level of evidence).

For adult patients with mild CD and low risk of progression, diet-based strategies along with careful monitoring for inadequate symptom relief, worsening inflammation, or disease progression may be considered.

We recommend against the use of oral mesalamine for induction or maintenance in patients with mildly to moderately active CD (strong recommendation, moderate level of evidence).

In general, clinical evidence of improvement should be evident within 2–4 weeks, and the maximal improvement should occur by 12–16 weeks.

View source ↗